SCHEMBL18530352

SCHEMBL18530352

NCCCCc1cccc(CC(=O)O)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.55
AKR1B1 P15121 1/20 0.48
GLS O94925 2/20 0.47
CYP1A2 P05177 1/20 0.46
CYP2C19 P33261 1/20 0.46
ALDH1A1 P00352 2/20 0.46
MAPT P10636 2/20 0.44
RXFP1 Q9HBX9 1/20 0.44
CYP4F2 P78329 1/20 0.43
CYP4A11 Q02928 1/20 0.43
HPGD P15428 2/20 0.43
HSD17B10 Q99714 2/20 0.43
HDAC3 O15379 1/20 0.43
MAPK1 P28482 1/20 0.43
ADRA1A P35348 1/20 0.43
HDAC4 P56524 1/20 0.43
SLC6A3 Q01959 1/20 0.43
HDAC1 Q13547 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4843183 0.87 TAAR1 (0.55) AKR1B1CYP1A2CYP2C19MAPTHPGD
SCHEMBL4402323 0.83 AKR1B1 (0.62) AKR1B1GLSCYP1A2CYP2C19ALDH1A1
Setogepram SCHEMBL289216 0.83 ALDH1A1 (0.69) ALDH1A1HPGDHSD17B10PPARGPPARA
Setogepram SCHEMBL29395927 0.83 ALDH1A1 (0.69) ALDH1A1HPGDHSD17B10PPARGPPARA
SCHEMBL27780871 0.82 SMN1; SMN2 (0.66) AKR1B1GLSCYP1A2CYP2C19MAPT
SCHEMBL2291602 0.82 ALDH1A1 (0.67) MAOAAKR1B1ALDH1A1MAPTRXFP1
SCHEMBL15199282 0.81 ALDH1A1 (0.67) ALDH1A1HPGDHSD17B10PPARGPPARA
SCHEMBL15865593 0.81 MAOA (0.53) MAOA
SCHEMBL28899619 0.81 ALDH1A1 (0.67) ALDH1A1HPGDHSD17B10PPARGPPARA
Setogepram SCHEMBL19095289 0.81 ALDH1A1 (0.67) ALDH1A1HPGDHSD17B10PPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250228944-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS ARVINAS OPERATIONS, INC. 2025-07-17 US disclosed
US-12171831-B2 Compounds and methods for the targeted degradation of bromodomain- containing proteins ARVINAS OPERATIONS, INC. (US) 2024-12-24 US disclosed
US-20230263893-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS ARVINAS OPERATIONS, INC. 2023-08-24 US disclosed
US-11554171-B2 Compounds and methods for the targeted degradation of bromodomain-containing proteins ARVINAS OPERATIONS, INC. (US) 2023-01-17 US disclosed
US-20210187108-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS ARVINAS OPERATIONS, INC. 2021-06-24 US disclosed
US-10772962-B2 Compounds and methods for the targeted degradation of bromodomain-containing proteins ARVINAS OPERATIONS, INC. (US) 2020-09-15 US disclosed
EP-3337476-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS Arvinas, Inc. (US) 2018-06-27 EP disclosed
US-20170065719-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS ARVINAS OPERATIONS, INC. 2017-03-09 US disclosed
WO-2017030814-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS Arvinas, Inc. (US) 2017-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10772962-B2 Compounds and methods for the targeted degradation of bromodomain-containing proteins BRPF3, STUB1, BRDT MAOA 2892/4885AKR1B1 2683/4885GLS 2790/4885
US-11554171-B2 Compounds and methods for the targeted degradation of bromodomain-containing proteins BRPF3, STUB1, BRDT MAOA 2892/4885AKR1B1 2683/4885GLS 2790/4885
US-20210187108-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS BRPF3, STUB1, BRDT MAOA 2892/4885AKR1B1 2683/4885GLS 2790/4885
US-12171831-B2 Compounds and methods for the targeted degradation of bromodomain- containing proteins BRPF3, STUB1, BRDT MAOA 2892/4885AKR1B1 2683/4885GLS 2790/4885
US-20230263893-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS BRPF3, STUB1, BRDT MAOA 2892/4885AKR1B1 2683/4885GLS 2790/4885
US-20250228944-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS BRPF3, STUB1, BRDT MAOA 2892/4885AKR1B1 2683/4885GLS 2790/4885
US-20170065719-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS BRPF3, STUB1, BRDT MAOA 2892/4885AKR1B1 2683/4885GLS 2790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.